| Bioactivity | BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor . BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial thromboplastin time, and decreases exposure dependently in FXI clotting activity[1]. | ||||||||||||
| Name | BMS-962212 | ||||||||||||
| CAS | 1430114-34-3 | ||||||||||||
| Formula | C32H28ClFN8O5 | ||||||||||||
| Molar Mass | 659.07 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Perera V, et al. First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects. Br J Clin Pharmacol. 2018 May;84(5):8 |
BMS-962212
CAS: 1430114-34-3 F: C32H28ClFN8O5 W: 659.07
BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor . BMS-962212 is well tolerated, with fast onse
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.